Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assays
Aim: Apolipoprotein E (ApoE) isoforms, especially the ApoE4 isoform, are genetic risk factors for Alzheimer’s disease (AD). Moreover, the APOE ε4 haplotype has a dose-dependent association with an increased risk of amyloid-related imaging abnormalities (ARIA) in individuals receiving disease-modifyi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2023-10-01
|
| Series: | Exploration of Neuroscience |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/en/Article/100624 |
| _version_ | 1827792608157499392 |
|---|---|
| author | Tatsushi Yuri Rosina Degrieck Dagmara Minczakiewicz Hideo Sato Jo Kamada Takuya Nakazawa Ina Vandenbroucke Katsumi Aoyagi Hisashi Nojima |
| author_facet | Tatsushi Yuri Rosina Degrieck Dagmara Minczakiewicz Hideo Sato Jo Kamada Takuya Nakazawa Ina Vandenbroucke Katsumi Aoyagi Hisashi Nojima |
| author_sort | Tatsushi Yuri |
| collection | DOAJ |
| description | Aim: Apolipoprotein E (ApoE) isoforms, especially the ApoE4 isoform, are genetic risk factors for Alzheimer’s disease (AD). Moreover, the APOE ε4 haplotype has a dose-dependent association with an increased risk of amyloid-related imaging abnormalities (ARIA) in individuals receiving disease-modifying therapy for AD. Therefore, the importance of APOE genotyping or proteotyping has been highlighted. Here, the authors developed fully automated chemiluminescence enzyme-immunoassay kit for ApoE4 and Pan-ApoE, and evaluated their diagnostic concordance with the APOE genotyping. Methods: One hundred seventy-eight specimens were analyzed using the Lumipulse® G ApoE4 and Pan-ApoE for the ApoE proteotype and evaluated its diagnostic concordance with the APOE genotype. Results: The ApoE4 kit specifically detected the ApoE4 concentration in plasma samples, and the polymorphism could be classified clearly by the ratio of ApoE4 and Pan-ApoE amount in plasma. Conclusions: The combination of Pan-ApoE and ApoE4-specific chemiluminescent enzyme immunoassay (CLEIA) assay is useful for predicting APOE ε4 allele status. |
| first_indexed | 2024-03-11T18:05:31Z |
| format | Article |
| id | doaj.art-cad32fef4dc64d4b93b174370017969b |
| institution | Directory Open Access Journal |
| issn | 2834-5347 |
| language | English |
| last_indexed | 2024-03-11T18:05:31Z |
| publishDate | 2023-10-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Neuroscience |
| spelling | doaj.art-cad32fef4dc64d4b93b174370017969b2023-10-17T07:43:44ZengOpen Exploration Publishing Inc.Exploration of Neuroscience2834-53472023-10-012523824410.37349/en.2023.00024Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assaysTatsushi Yuri0Rosina Degrieck1 Dagmara Minczakiewicz2https://orcid.org/0009-0005-2996-6698Hideo Sato3Jo Kamada4Takuya Nakazawa5Ina Vandenbroucke6Katsumi Aoyagi7https://orcid.org/0000-0003-3818-7985Hisashi Nojima8https://orcid.org/0000-0002-8907-5767Product Development Department, Product Designing 1st section, Fujirebio Inc., Tokyo 107-0052, Japan; Product Development Department, Fujirebio Europe N.V., 9052 Gent, BelgiumProduct Development Department, Fujirebio Europe N.V., 9052 Gent, BelgiumProduct Development Department, Fujirebio Europe N.V., 9052 Gent, BelgiumFundamental Research Department, Assay Technology Research Section, Fujirebio Inc., Tokyo 107-0052, JapanProduct Development Department, Product Designing 1st section, Fujirebio Inc., Tokyo 107-0052, JapanProduct Development Department, Product Designing 1st section, Fujirebio Inc., Tokyo 107-0052, JapanProduct Development Department, Fujirebio Europe N.V., 9052 Gent, BelgiumResearch and Development Division, Fujirebio Inc., Tokyo 107-0052, JapanProduct Development Department, Product Designing 1st section, Fujirebio Inc., Tokyo 107-0052, JapanAim: Apolipoprotein E (ApoE) isoforms, especially the ApoE4 isoform, are genetic risk factors for Alzheimer’s disease (AD). Moreover, the APOE ε4 haplotype has a dose-dependent association with an increased risk of amyloid-related imaging abnormalities (ARIA) in individuals receiving disease-modifying therapy for AD. Therefore, the importance of APOE genotyping or proteotyping has been highlighted. Here, the authors developed fully automated chemiluminescence enzyme-immunoassay kit for ApoE4 and Pan-ApoE, and evaluated their diagnostic concordance with the APOE genotyping. Methods: One hundred seventy-eight specimens were analyzed using the Lumipulse® G ApoE4 and Pan-ApoE for the ApoE proteotype and evaluated its diagnostic concordance with the APOE genotype. Results: The ApoE4 kit specifically detected the ApoE4 concentration in plasma samples, and the polymorphism could be classified clearly by the ratio of ApoE4 and Pan-ApoE amount in plasma. Conclusions: The combination of Pan-ApoE and ApoE4-specific chemiluminescent enzyme immunoassay (CLEIA) assay is useful for predicting APOE ε4 allele status.https://www.explorationpub.com/Journals/en/Article/100624apolipoprotein e4alzheimer’s diseasedisease modifying therapychemiluminescent enzyme immunoassay |
| spellingShingle | Tatsushi Yuri Rosina Degrieck Dagmara Minczakiewicz Hideo Sato Jo Kamada Takuya Nakazawa Ina Vandenbroucke Katsumi Aoyagi Hisashi Nojima Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assays Exploration of Neuroscience apolipoprotein e4 alzheimer’s disease disease modifying therapy chemiluminescent enzyme immunoassay |
| title | Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assays |
| title_full | Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assays |
| title_fullStr | Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assays |
| title_full_unstemmed | Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assays |
| title_short | Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assays |
| title_sort | estimation of the allelic status of apolipoprotein e4 isoforms with fully automated lumipulse r assays |
| topic | apolipoprotein e4 alzheimer’s disease disease modifying therapy chemiluminescent enzyme immunoassay |
| url | https://www.explorationpub.com/Journals/en/Article/100624 |
| work_keys_str_mv | AT tatsushiyuri estimationoftheallelicstatusofapolipoproteine4isoformswithfullyautomatedlumipulseassays AT rosinadegrieck estimationoftheallelicstatusofapolipoproteine4isoformswithfullyautomatedlumipulseassays AT dagmaraminczakiewicz estimationoftheallelicstatusofapolipoproteine4isoformswithfullyautomatedlumipulseassays AT hideosato estimationoftheallelicstatusofapolipoproteine4isoformswithfullyautomatedlumipulseassays AT jokamada estimationoftheallelicstatusofapolipoproteine4isoformswithfullyautomatedlumipulseassays AT takuyanakazawa estimationoftheallelicstatusofapolipoproteine4isoformswithfullyautomatedlumipulseassays AT inavandenbroucke estimationoftheallelicstatusofapolipoproteine4isoformswithfullyautomatedlumipulseassays AT katsumiaoyagi estimationoftheallelicstatusofapolipoproteine4isoformswithfullyautomatedlumipulseassays AT hisashinojima estimationoftheallelicstatusofapolipoproteine4isoformswithfullyautomatedlumipulseassays |